Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations
Authors:
- 1 March 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (3) , 320-326
Abstract
ImportanceAntiemetics are used to prevent chemotherapy-induced nausea and vomiting in patients with cancer. Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have increased efficacy but are expensive. The American Society of Clinical Oncology’s first guideline in the 2013 Choosing Wisely (CW) campaign discouraged overuse of expensive antiemetics in patients with low risk of chemotherapy-induced nausea and vomiting. However, little is known about patterns or trends in antiemetic overuse or whether any change has occurred with the publication of the CW recommendations.ObjectiveTo estimate the baseline prevalence, trends, determinants, and costs of antiemetic overuse from January 1, 2008, through March 31, 2015.Design, Setting, and ParticipantsFrom January 1, 2008, through March 31, 2015, this observational study applied descriptive (univariate and bivariate) and multivariable logistic regression analyses to longitudinal health insurance enrollment and nationwide MarketScan insurance claims data for 678 220 privately insured patients receiving chemotherapy before and after the October 29, 2013, announcement of the CW guidelines. The baseline prevalence, trends, determinants, and costs of antiemetic overuse were estimated in cases stratified by risk for chemotherapy-induced nausea and vomiting.Main Outcomes and MeasuresAntiemetic use, overuse measure, and expenses before and after the publication of the CW recommendation, with adjustment for patient and health care professional characteristics.ResultsThe sample included 678 220 adults who started chemotherapy during the observation period. The average age of the sample was 59.5 years, with 58.2% (n = 394 724) female. Antiemetic overuse occurred in 24.1% (n = 163 451) of patients, with highest rates among those receiving intravenous chemotherapy with high chemotherapy-induced nausea and vomiting risk (32.4% [n = 106 795]). Compared with baseline before the CW, patients had 7.0% lower odds of antiemetic overuse (95% CI, 4.4%-9.5%) during the 6 months after the CW, but this decrease was transitory: the odds of antiemetic overuse were 7.4% (95% CI, 4.6%-10.2%) higher than baseline at 6 months after the CW. Low-risk intravenous chemotherapy agents had overuse that continued to decrease 6 months after the CW. Antiemetic overuse was associated with higher costs. Reducing antiemetic overuse could have paid for 6.1% (95% CI, 5.8%-6.4%) of the chemotherapy drug costs.Conclusions and RelevanceAntiemetic overuse is prevalent and results in unnecessary spending associated with systemic chemotherapy treatment. Short-term decreases in antiemetic overuse were associated with the CW recommendation, but sustained decreases occurred in only one risk group.Keywords
This publication has 18 references indexed in Scilit:
- Cancer care cost trends in the United States: 1998 to 2012Cancer, 2016
- Early Trends Among Seven Recommendations From the Choosing Wisely CampaignJAMA Internal Medicine, 2015
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health InsurerJournal of Oncology Practice, 2015
- Use of Imaging for Staging of Early-Stage Breast Cancer in Two Integrated Health Care Systems: Adherence With a Choosing Wisely RecommendationJournal of Oncology Practice, 2015
- Choosing Wisely? Patterns and Correlates of the Use of Hypofractionated Whole-Breast Radiation Therapy in the State of MichiganInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Appropriateness of Imaging for Lung Cancer Staging in a National CohortJournal of Clinical Oncology, 2014
- Quality Oncology Practice Initiative: An Approach to Solving the Value EquationJournal of Oncology Practice, 2014
- American Society of Clinical Oncology 2013 Top Five List in OncologyJournal of Clinical Oncology, 2013
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011